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Bortezomib (BTZ) is a first-in-class proteasome inhibitor approved for the therapy of 
multiple myeloma that also displays unique regulatory activities on immune cells. The 
enzyme indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan metabolizing enzyme 
exerting potent immunoregulatory effects when expressed in dendritic cells (DCs), the 
most potent antigen-presenting cells capable of promoting either immunity or tolerance. 
We previously demonstrated that, in inflammatory conditions, IDO1 is subjected to 
proteasomal degradation in DCs, turning these cells from immunoregulatory to immuno-
stimulatory. In non-obese diabetic (NOD) mice, an experimental model of autoimmune 
diabetes, we also identified an IDO1 defect such that the DCs do not develop tolerance 
toward pancreatic islet autoantigens. We found that BTZ rescues IDO1 protein expres-
sion in  vitro in a particular subset of DCs, i.e., plasmacytoid DCs (pDCs) from NOD 
mice. When administered in vivo to prediabetic mice, the drug prevented diabetes onset 
through IDO1- and pDC-dependent mechanisms. Although the drug showed no ther-
apeutic activity when administered alone to overtly diabetic mice, its combination with 
otherwise suboptimal dosages of autoimmune-preventive anti-CD3 antibody resulted 
in disease reversal in 70% diabetic mice, a therapeutic effect similar to that afforded by 
full-dosage anti-CD3. Thus, our data indicate a potential for BTZ in the immunotherapy 
of autoimmune diabetes and further underline the importance of IDO1-mediated immune 
regulation in such disease.
Keywords: tryptophan metabolism, indoleamine 2,3-dioxygenase 1 enzyme, dendritic cells, proteasome, 
autoimmune diabetes, immune regulation, anti-cD3 antibody
inTrODUcTiOn
Dendritic cells (DCs) have an important role as islet antigen-presenting cells in the initiation of 
autoimmune diabetes in the non-obese diabetic (NOD) mouse, in which defective tryptophan 
catabolism by immune regulatory indoleamine 2,3-dioxygenase 1 (IDO1) contributes to an overall 
impaired tolerogenesis. Functional flexibility represents a feature of plasmacytoid DCs (pDCs), 
capable of inducing either immune activation or tolerance, depending on environmental conditions 
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(1–5). Protein expression of IDO1—and thus the functional 
balance between immunity and tolerance—can greatly vary in 
pDCs in response to transcriptional Ido1 inducers as well as post-
transcriptional mechanisms. Splenic pDCs from conventional 
(e.g., C57BL/6 or BALB/c) mice express basal yet low levels of 
IDO1 protein, which can be increased by interferon (IFN)-γ, the 
standard IDO1 transcriptional inducer. As a result, unstimulated 
splenic pDCs are immunogenic, whereas IFN-γ-stimulated pDCs 
are tolerogenic (6, 7). The post-transcriptional mechanisms 
include, instead, proteasomal degradation of the enzyme, which 
is driven by inflammatory IL-6 and results in sustained inflam-
mation and impaired tolerogenesis (4, 6–8).
In NOD mice, IDO1 expression and activity in pDCs are 
almost negligible in response to IFN-γ (9, 10), due to an impaired 
IFN-γ signaling activity (9) and abnormal regulatory proteolysis 
of the enzyme sustained by high levels of IL-6 (10). In agreement 
with this, systemic administration of IL-6-neutralizing antibodies 
results in marked suppression of the diabetic condition in NOD 
animals (11). Moreover, inflammatory cytokines, such as IFN-γ 
and tumor necrosis factor-α, induce the synthesis of catalytic 
subunits of the immunoproteasome—LMP2/β1i, MECL1/β2i, 
and LMP7/β5i—which replace their constitutive proteasome 
counterparts in hematopoietic cells (12). Selective inhibition of 
the β5i subunit has been shown to control disease progression 
in a series of experimental autoimmune disorders and promote 
long-term allograft survival (13–17).
Bortezomib (BTZ) is a reversible proteasome inhibitor that 
possesses immune regulatory activities that span various cellular 
processes of T and DCs essential for the development of adaptive 
immune responses (18). BTZ suppresses T-cell activation and 
production of cytokines, inhibits T-cell mobilization, suppresses 
T-cell growth and proliferation, and induces T-cell apoptosis. In 
DCs, BTZ suppresses maturation and function, cytokine produc-
tion, and induces apoptosis. The drug can also inhibit nuclear 
translocation of NF-κB family members in DCs, thus supporting 
a pleiotropic function of BTZ in regulating DC function at the 
interface between immunity and tolerance (19).
Here, we report that BTZ confers tolerogenic effects on pDCs 
from NOD mice, resulting in enhanced generation of regulatory 
T cells and preventing diabetes onset in mice through an IDO1-
dependent mechanism. A combination of BTZ and otherwise 
suboptimal dosages of anti-CD3 was found to rescue normogly-
cemia in overtly diabetic NOD mice.
aniMals anD MeThODs
animals
Female BALB/c and NOD/MrkTac female mice, aged 6–16 
weeks, were purchased from Charles River Breeding Laboratories 
(Calco, Milan, Italy) and Taconic (Albany, NY, USA), respectively. 
IDO1-deficient (Ido1−/−) NOD female mice were bred at the 
animal facility of the University of Perugia.
cell Purification and In Vitro Treatments
Cells were isolated from pancreatic lymph nodes (pLNs) and 
pancreata by digestion with collagenase type IV (Sigma-Aldrich, 
St. Louis, MO, USA); total peritoneal cells (PeCs) were isolated 
from the peritoneal washes by centrifugation. Unfractionated 
cell populations were promptly used for cytofluorimetric analysis 
or incubated at 37°C for 16 h for cytokines and/or kynurenines 
detection in culture supernatants. All purification procedures 
involving pDCs and conventional DCs (cDCs, CD11c+ CD8−) 
have previously been described (6, 7, 9). The purity of DC popula-
tions was superior to 90%. Purified pDCs were exposed at 37°C 
to 200 U/ml of recombinant IFN-γ (R&D Systems, Minneapolis, 
MN, USA) or to 10 nM of BTZ (LC Laboratories, MA, USA) in 
the presence or absence of 4 μM 1-methyl-DL-tryptophan (1-MT; 
Sigma-Aldrich, St. Louis, MO, USA), a standard IDO1 inhibitor. 
In selected experiments, pDCs pretreated as described above, 
were co-cultured (2:1 cell ratio) with CD4+CD25− T lymphocytes 
purified from pLNs, and maintained at 37°C for 96 h, before har-
vesting the supernatants for the cytokine analysis and the cells for 
cytofluorimetric analysis.
Western Blot, elisa, and cytofluorimetric 
analyses
Indoleamine 2,3-dioxygenase 1 protein expression was inves-
tigated in pDCs by immunoblot with a rabbit polyclonal anti- 
mouse IDO1 antibody raised in our laboratory (20). Anti-β-
tubulin antibody (Sigma-Aldrich) was used as a normalizer. 
Mouse IL-6, IL-17A, IFN-γ, IL-10, and TGF-β1 were measured 
in culture supernatants by ELISA with specific kits (eBioscience, 
Inc., San Diego, CA, USA; Promega Italia, S.r.l., Milano, Italy). An 
ELISA–based TransAM Flexi NF-κB Family Kit (Active Motif, 
Rixensart, Belgium) was used to monitor activity of NF-κB family 
members, as described (6, 7, 10). Cytofluorimetric assays were 
conducted using the specific fluorochrome-labeled antibodies for 
murine CD19, CD5, CD1d, CD4, Foxp3, and RORγt (Biolegend, 
BD Pharmingen, eBiocience Inc., San Diego, CA, USA; Miltenyi 
Biotech, Germany), as described (6). For intracellular staining of 
Foxp3 and RORγt, cells were previously permeabilized by the Fix/
Perm Buffer set (Biolegend, San Diego, CA, USA).
Kynurenine assay
The functional activity of IDO1 was measured in vitro in terms 
of the ability to metabolize tryptophan (Trp) to kynurenine 
(Kyn), whose concentration was measured by high-performance 
liquid chromatography (HPLC) in culture supernatants after 
the addition of 100  µM Trp (20). Systemic Kyn/Trp ratio was 
determined in deproteinated sera of mice by measuring Kyn and 
Trp concentrations by HPLC.
In Vivo Treatment and histopathology  
in nOD Mice
Bortezomib was administered i.p. at the dose of 0.10 or 0.25   
mg/kg, a dose well below the drug’s maximum tolerated dose, 
i.e., 0.5 mg/kg (21), every other day for 2 weeks in prediabetic or 
in overtly diabetic NOD mice. In selected experiments, overtly 
diabetic mice were coadministered with BTZ and anti-CD3 (145-
2C11) F(ab′)2 fragments (22) (provided by Lucienne Chatenoud, 
Université Paris Descartes, Paris) i.v. at a suboptimal dose of 10  
µg/day, for five consecutive days. Selected groups of mice received 
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the standard IDO1 inhibitor 1-MT in their drinking water at the 
concentration of 2 mg/ml. In vivo depletion of pDCs occurred 
1 week after commencing BTZ treatment, by injecting prediabetic 
NOD mice with 250 μg/mouse of 120G8 (IgG2a isotype) antibody 
i.p., as described (23). Animals were either monitored for glyce-
mia or sacrificed for ex vivo analyses at different times of drug 
treatment(s). For histopathology, 3–4 µm of paraffin-embedded 
sections of pancreata (5/organ) were stained with hematoxylin 
and eosin and analyzed by light microscopy. Insulitis scoring was 
done according to standard criteria as described (24).
skin Test assay
A skin test assay was used for measuring delayed-type hypersen-
sitivity (DTH) in response to challenge in the footpad with the 
diabetogenic H-2Kd-restricted IGRP peptide (VYLKTNVFL), 
as described (7), using prediabetic NOD mice as recipients. 
For in vivo immunization, 3 × 105 peptide-loaded NOD cDCs, 
combined with a minority fraction (5%) of peptide-loaded NOD 
pDCs, and pre-incubated in  vitro as indicated in the relevant 
figure legends, were injected subcutaneously into recipient mice. 
Two weeks later, a DTH response was measured to intrafootpad 
challenge with the eliciting peptide, and results were expressed as 
the change in footpad weight of peptide-injected footpads over 
that of vehicle-injected (internal control) counterparts (4, 6, 9).
statistical analysis
In vitro studies comparing more than two experimental condi-
tions were analyzed by ANOVA test followed by Dunnett’s or 
Bonferroni test, while Student’s t-test was used for the analysis 
of in vitro results comparing two conditions. In the in vivo skin 
test assay, a paired Student’s t-test was used for statistical analysis 
by comparing the weight change of the experimental footpads 
with vehicle-injected counterpart (9). Diabetes incidence was 
plotted by using the Kaplan–Meier method, i.e., a non-parametric 
cumulative survival plot. The statistical comparison between the 
curves was performed by using the log-rank (Mantel–Cox) test.
resUlTs
BTZ confers iDO1-Dependent Tolerogenic 
effects on pDcs from nOD Mice
We initially examined whether proteasome inhibition by BTZ 
would upregulate IDO1 expression and function in pDCs from 
NOD mice. In vitro, splenic pDCs, purified from prediabetic 
NOD mice, were incubated with 10 nM BTZ or 200 U/ml IFN-γ 
and, at different times, cell lysates and supernatants were analyzed 
for IDO1 protein and Kyn production, respectively. As expected, 
IFN-γ failed to upregulate IDO1 protein (Figure 1A) and activity 
(Figure 1B) in NOD pDCs. By contrast, pDCs conditioned with 
BTZ showed higher IDO1 expression (Figure 1A) and produced 
significantly higher levels of Kyn (Figure  1B). Although the 
increase in IDO1 protein expression was rather short-lived, treat-
ment of NOD pDCs with BTZ induced the appearance of high 
molecular-weight IDO1 proteins (Figure 1A), corresponding to 
poliubiquitinated forms of the protein. We also found significantly 
higher expression of Socs3—the IL-6-induced molecular driver 
of IDO1 proteasomal degradation—and of the immunoprotea-
some subunits in NOD, compared to BALB/c pancreata (Figure 
S1A in Supplementary Material) and in prediabetic vs. diabetic 
pDCs, purified from NOD pLNs (Figure S1B in Supplementary 
Material). Interestingly, prediabetic NOD pDCs were also 
featured by a higher expression of the gene set involved in the 
pro-inflammatory NF-κB pathway (Figure S1C in Supplementary 
Material), suggesting a more inflammatory-prone phenotype of 
pDCs in the early phase of the disease.
In vivo, NOD female mice were sensitized with the diabe-
togenic IGRP peptide loaded on highly immunogenic NOD 
cDCs. The cDCs were administered alone or in combination with 
a minority fraction of NOD pDCs, treated with control media, 
IFN-γ, or BTZ (the latter alone or in combination with the IDO1 
inhibitor 1-MT). Two weeks later, in vivo IGRP-specific immune 
reactivity was assayed. As expected, the priming ability of immu-
nostimulatory cDCs was not affected by the presence of untreated 
or IFN-γ-stimulated NOD pDCs. However, co-administration of 
BTZ-treated pDCs ablated the IGRP-specific reactivity elicited by 
cDCs. The suppressive effect of BTZ-conditioned pDCs was, how-
ever, lost when 1-MT treatment was applied only in concurrence 
with BTZ exposure (Figure  1C). These data clearly show that 
BTZ—unlike IFN-γ—regulates the quantitative and qualitative 
expression of IDO1 protein in prediabetic NOD pDCs, restoring 
their tolerogenic potential in  vivo. In addition to the signaling 
defect previously described (9), post-transcriptional anomalies 
were found to contribute to the failure of IFN-γ to enhance IDO1 
expression in NOD mice.
BTZ-conditioned nOD pDcs Favor the 
Differentiation of regulatory rather Than 
effector T cells In Vitro
Next, we investigated the ability of BTZ-conditioned NOD pDCs 
to affect T-cell differentiation and/or function when cocultured 
with CD4+ T  cells. In the pDC-CD4+ T-cell cocultures, BTZ-
pretreated pDCs significantly decreased IL-6, IFN-γ (as T helper 
1 marker), and IL-17 (as T helper 17 marker) in the coculture 
supernatant, and IL-10 but not TGF-β was instead increased 
(Figure 2A). An analogous cytokine profile was observed after 
BTZ conditioning of the pDCs alone (Figure S2 in Supplementary 
Material). Interestingly, the co-presence of 1-MT at the time of 
pDCs exposure to BTZ selectively negated the drug effect on 
the pro-inflammatory cytokine (i.e., IL-6 and IFN-γ) secretion 
profile (Figure 2A), suggesting that IDO1 upregulation by BTZ 
could play a role in controlling those cytokines. Cytofluorimetric 
analysis conducted at the end of the coculture showed that BTZ-
pretreated pDCs induced a twofold increase in the percentage 
of CD4+Foxp3+ T  cells, an effect negated by 1–MT, the IDO1 
inhibitor (Figures 2B,C).
In immune cells, BTZ has been shown to downregulate the 
production of several pro-inflammatory cytokines, presumably 
via inhibition of NF-κB activation (25, 26). Moreover, prediabetic 
pDCs showed a higher expression of the pro-inflammatory 
NF-κB pathway compared to diabetic pDCs (Figure S1C in 
Supplementary Material). To evaluate any role for impaired 
NF-κB activation by BTZ in our setting, pDCs purified from 
FigUre 1 | Bortezomib (BTZ) restores the tolerogenic potential of prediabetic non-obese diabetic (nOD) plasmacytoid Dcs (pDcs) in an indoleamine 
2,3-dioxygenase 1 (iDO1)-dependent fashion. (a) IDO1 immunoblot analysis of cell lysates from splenic pDCs purified from prediabetic NOD mice incubated 
with BTZ for the indicated time, interferon (IFN)-γ or medium alone for 24 h. One representative experiment out of three is shown. (B) IDO1 activity measured in 
terms of kynurenine production in cell supernatant of pDCs incubated as in panel (a). *p < 0.05; **p < 0.01 (one-way ANOVA and Dunnett’s multiple comparison 
test). Data are presented as means ± SD from triplicate samples. (c) IGRP-pulsed prediabetic NOD conventional DCs in combination with a minority fraction (5%) of 
NOD pDCs with no conditioning (control) or in vitro conditioned with 1-MT, IFN-γ, BTZ alone, or in combination with 1-MT, were transferred into NOD recipient mice 
(n = 6/group) to be assayed for skin reactivity to the eliciting peptide. Analysis of skin test reactivity is presented as change in footpad weight. *p < 0.05; **p < 0.01; 
***p < 0.001 (paired Student’s t-test; weight change of experimental vs. control footpad).
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NOD mice were incubated with 10 nM BTZ or medium alone and 
the activation of NF-κB was evaluated in nuclear cell lysates after 
60 and 90 min. A significant reduced nuclear translocation of p50 
and p65 canonical subunits could be observed after 60  min in 
BTZ-treated as compared to untreated NOD pDCs; at a later time 
(90 min) a significant nuclear translocation of the non-canonical 
subunits p52 and RelB could be observed (Figure  2D). The 
presence of BTZ in the cell culture significantly modified the 
transcriptional activity of NF-κB, shifting the balance toward 
the non-canonical pathway, which we have previously shown as 
being involved in the transcription of Ido1 (6, 7).
Overall, these data suggested that the BTZ exposure of 
inflammation-prone pDCs—such as those from NOD mice 
(27, 28)—would tip the balance between inflammatory and 
immunoregulatory signals in favor of the latter, via upregulation 
of the IDO1 mechanism and also via correction of a dysfunctional 
NF-κB activity.
BTZ Prevents Diabetes Development  
in nOD Mice
Because IDO1 has been shown to play a major role in the protec-
tion from the experimental autoimmune diabetes (10, 24, 29, 30), 
we performed in vivo experiments to ascertain whether BTZ could 
exert protective effects in NOD mice. Groups of female NOD 
mice in prediabetes were thus administered BTZ i.p. at 0.10 or 
0.25 mg/kg every other day for 2 weeks, a well-tolerated regimen, 
and glycemia was regularly measured. Over time, approximately 
80% of control mice, and mice given the lower BTZ dose, devel-
oped overt diabetes, with glycemia values exceeding 250 mg/dl. 
By contrast, only 20% of mice administered BTZ at 0.25 mg/kg 
became hyperglycemic (Figure  3A), and glycemia values of 
protected mice remained in the range of 120–170  mg/dl over 
time (Figure 3B). In mice administered 0.25 mg/kg BTZ, histol-
ogy of the pancreata revealed the presence of preserved islets, 
without invasive insulitis or with minimum or no peri-insulitis. 
The great majority of islets of the control and mice receiving the 
lower BTZ dose was characterized by immune cell infiltration 
(Figures 3C,D).
In order to investigate the in vivo effects of BTZ on immune cells, 
additional groups of mice, receiving 0.25 mg/kg BTZ or vehicle 
treatment, were sacrificed at different times (day +3 and day +100 
after the last drug administration) and used as source of pancreas, 
pLNs, and PeCs—peritoneum being the site of BTZ injection—to 
be analyzed for T and B cell populations, cytokine production, 
and IDO1 expression. Cytofluorimetric analyses showed that, at 
FigUre 2 | Bortezomib (BTZ) conditions inflammatory-prone non-obese diabetic plasmacytoid Dcs (pDcs) toward immunoregulatory signals.  
(a) Secretion of IL-6, IL-17, interferon (IFN)-γ, IL-10, and TGF-β in supernatant of pDC-CD4+ T cell cocultures, where pDCs were pretreated with BTZ alone or in 
combination with 1-MT, or left untreated (medium) for 24 h. *p < 0.05; **p < 0.01; ***p < 0.001 (one-way ANOVA and Dunnett’s multiple comparison test). Results in 
panel (a) are representative of three different experiments (mean ± SD). (B) Representative flow cytometric dot plots illustrating the frequency of CD4+Foxp3+ cells 
among CD4+CD25− T cells cultured for 4 days together with pDCs treated as in panel (a). (c) Percentage of CD4+Foxp3+ cells in a CD4+CD25− T cells population 
cultured for 4 days together with pDCs treated as in panel (a). *p < 0.05; **p < 0.01 (one-way ANOVA followed by Bonferroni multiple comparison test). Results are 
representative of three different experiments (mean ± SD). (D) ELISA detection of p65, p50, p52, and RelB subunits of NF-κB in nuclear extracts of pDCs untreated 
(dotted line) or treated with BTZ for 60 and 90 min. Results are presented as fold change of the absorbance at 450 nm (Fold A450). *p < 0.05 (paired Student’s t-test; 
treated vs. untreated samples). Data are presented as means ± SD from triplicate samples.
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3 and more so 100 days, the drug significantly increased percent-
ages of CD4+ Foxp3+ (Treg) and CD19+ CD5+ CD1d+ (Breg) cells 
in pancreas and pLNs but not in PeCs. In parallel, a decrease in 
CD4+ RORγt+ T cells (i.e., Th17 subset) was found in pLNs and 
later on (day +100) in pancreata (Figure 3E). Cytokine analysis of 
the same sources cultured for 24 h revealed most evident changes 
in IL-6 production, which started to decrease as soon as on day 
+3 in the pancreas of BTZ-treated mice relative to controls and in 
pLNs as well, though later in time (day +100; Figure 3F). An early 
(day +3) IL–17A decrease was also found in cultured pLNs and 
it persisted longer (day +100), whereas, in the pancreas, IL-17A 
decreased only later in time (day +100). IFN-γ decreased early in 
pLNs and PeCs and the effect persisted in pLNs up to day +100. 
Release of IL-10, but not of TGF-β, was increased on day +3 in all 
supernatants from whichever source and it remained increased in 
the pancreas and pLNs on day +100 (Figure 3F). IDO1 protein 
expression appeared to be upregulated in pancreas and pLNs, but 
not in PeCs from mice administered BTZ (Figure 3G). Moreover, 
the Kyn/Trp ratio increased in sera from mice treated with BTZ 
(Figure 3H).
Thus, our in vivo data indicated that proteasomal inhibition 
is effective in preventing development of autoimmune diabetes 
in a significant percentage of mice and that the protective 
effect is accompanied by a decrease in pro-inflammatory effec-
tor (Th17) cells and cytokines (IL-6, IL-17A, and IFN-γ), as 
well as by an increase in regulatory (Treg and Breg) cells and 
anti-inflammatory IL-10. Moreover, the in  vivo treatment with 
BTZ upregulated IDO1 protein in the pancreas and pLNs and 
increased the systemic Kyn/Trp ratio. Importantly, changes were 
most evident in the pancreas, in immune cells draining (pLNs), 
and in proximity of the pancreas (namely, peritoneum, which was 
also the injection site).
FigUre 3 | continued
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Prevention of Diabetes by BTZ requires 
iDO1 and pDcs
Based on the ability of BTZ to rectify IDO1 expression and activity 
in pDCs in vitro, we evaluated whether the protective effect of the 
drug in vivo could be mediated by IDO1 and pDCs. To this pur-
pose, mice were administered BTZ at 0.25 mg/kg as in Figure 3A, 
with or without 1-MT, the inhibitor of IDO1. Mice receiving 
vehicle alone were used as a control. IDO1 blockade completely 
abrogated the protective effect of BTZ (Figure  4A). Similarly, 
BTZ protection was lost in Ido1−/− NOD mice (Figure 4B). In vivo 
depletion of pDCs (23) occurring at the time of BTZ administra-
tion negated the protective effect of the proteasomal inhibitor 
against diabetes development (Figure  4C), whereas depletion 
of pDCs occurring before BTZ treatment would not ablate its 
anti-diabetic effect (data not shown). Of interest, administration 
of anti-PDCA1 in the absence of BTZ also significantly reduced 
the percentage of animals that developed diabetes over time 
(Figure 4D). Although difficult to explain at this time, the fact 
that pDC depletion per se exerted protective effects in untreated 
prediabetic NOD mice may confirm previous results indicating 
that pDCs can be pathogenic in NOD mice (31), and BTZ may 
help restoring an anti-inflammatory phenotype in NOD pDCs, 
so that depletion of pDCs during the treatment turns out to be 
detrimental as it abrogates the protective effect of BTZ.
Overall, our data indicated that proteasome inhibition is effec-
tive in the prevention of experimental autoimmune diabetes and 
that the effect requires pDCs and IDO1-mediated tryptophan 
catabolism.
FigUre 3 |  administration of bortezomib (BTZ) prevents the development of autoimmune diabetes in non-obese diabetic (nOD) mice. (a) Prediabetic 
female NOD mice (n = 8) were intraperitoneally administered with vehicle alone (control; white circles), BTZ at 0.10 mg/kg (white triangles) or 0.25 mg/kg (black 
squares), and blood glucose was monitored over time. Diabetes was diagnosed in mice with blood glucose level ≥250 mg/dl and results are reported as diabetes 
incidence. **p < 0.01 (log-rank Mantel–Cox test). (B) Single blood glucose concentrations of NOD mice treated as in panel (a). (c) Pancreatic histology of mice 
treated as in panel (a) (scale bar, 100 µm; representative islet area for each group are shown). (D) Islets were scored to record percentages of islets of a given score 
over total number of islets (20–30/pancreas). One experiment is depicted of three with similar results. (e) Cytofluorimetric analysis of the frequency of Foxp3+ and 
RORγt+ cells among CD4+ T cell population and CD19+CD5+CD1d+ cells in pancreas, pancreatic lymph nodes (pLNs) and peritoneal cells (PeCs) from prediabetic 
female NOD mice treated with BTZ at 0.25 mg/kg or vehicle alone (control) and sacrificed at day +3 or day +100 after the last drug treatment. *p < 0.05 and 
**p < 0.01 (unpaired Student’s t-test, BTZ-treated vs. control mice). (F) Detection of IL-6, IL-17A, IFN-γ, IL-10, and TGF-β in supernatant of unfractionated cells from 
pancreas, pLNs, and PeCs of mice treated as in panel (e) and cultured for 24 h. *p < 0.05 and **p < 0.01 (unpaired Student’s t-test, BTZ-treated vs. control mice 
for each cell type). (g) Indoleamine 2,3-dioxygenase 1 immunoblot analysis of cell lysates from pancreas, pLNs, and PeCs of mice treated as in panel (e). One 
representative experiment out of three is shown. (h) Kynurenine to tryptophan ratio (Kyn/Trp) measured in sera from mice treated as in panel (e). **p < 0.01 
(unpaired Student’s t-test, BTZ-treated vs. control mice). Data are presented as means ± SD for each group (n = 8 per group).
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a combination of BTZ and suboptimal 
anti-cD3 antibody rescues 
normoglycemia in Overtly Diabetic  
nOD Mice
Prompted by BTZ efficacy in preventing diabetes, we interrogated 
whether the drug would revert an ongoing disease. NOD female 
mice with hyperglycemia were i.p. administered BTZ at 0.1 or 
0.25 mg/kg every other day for 2 weeks. Apart from a transient 
and not significant reduction in glycemia at 1 week post-initiation 
of drug treatment, no therapeutic effect was afforded by BTZ 
(Figure 5A).
Previous studies have demonstrated that administration of 
non-mitogenic anti-CD3 represents an effective maneuver capa-
ble of rescuing normoglycemia in approximately 80% diabetic 
NOD mice (22). Maximum therapeutic effects are achieved at the 
dose of 50 µg administered i.v. for five consecutive days, and they 
relied on the release of TGF-β by Treg cells (32).
We thus became interested in ascertaining whether a com-
bination of BTZ and anti-CD3 would result in additive effects. 
Previous experiments (Chantal Kuhn and Lucienne Chatenoud, 
unpublished data) found that the suboptimal dose of 10  µg is 
capable of reverting hyperglycemia in a minority (less than 30%) 
of diabetic animals (Figure 5B). In our setting, a combination of 
BTZ at 0.25—but not 0.1—mg/kg and 10 µg anti-CD3 restored 
normoglycemia in 70% diabetic mice, a value significantly differ-
ent from that of mice on suboptimal anti-CD3 alone (Figure 5B).
Groups of mice, treated as in Figure 5B, were sacrificed at the 
end of the experiment and used as a source of pLNs to be assayed 
for IDO1 expression and activity as well as for cytokine produc-
tion. The combination of the two drugs greatly upregulated 
expression of IDO1 protein (Figure 5C) and activity (Figure 5D) 
in pLNs, compared to suboptimal anti-CD3 alone. Perhaps 
most importantly, at variance with the results in Figure 3F, the 
combined in  vivo treatment with BTZ and anti-CD3—but not 
either treatment alone—resulted in a significant increase in the 
production of TGF-β by pLNs, and it significantly reduced IL-6 
and increased IL-10 (Figure 5E).
Because we have previously demonstrated that TGF-β is a 
long-term inducer of IDO1 (6), our current data would further 
FigUre 4 | Prevention of autoimmune diabetes by bortezomib (BTZ) requires plasmacytoid Dcs and indoleamine 2,3-dioxygenase 1  
(iDO1)-mediated tryptophan catabolism. Diabetes was diagnosed in mice with blood glucose level ≥250 mg/dl and results are reported as diabetes incidence. 
(a) Prediabetic female non-obese diabetic (NOD) mice (n = 8) were intraperitoneally administered with vehicle (control; white circles), BTZ at 0.25 mg/kg alone  
(black squares) or in combination with 1-MT (black triangles), and blood glucose was monitored over time. (B) Prediabetic female Ido1−/− NOD mice (n = 8) were 
intraperitoneally administered with vehicle alone (control; white circles) or BTZ at 0.25 mg/kg (black squares), and blood glucose was monitored over time.  
(c) Prediabetic female NOD mice (n = 8) were intraperitoneally administered with BTZ at 0.25 mg/kg in combination with anti-PDCA1 depleting antibody  
(250 μg/mouse; white squares) or with the isotype control (rat IgG; black squares), and blood glucose was monitored over time. (D) Diabetic incidence of prediabetic 
NOD mice treated with anti-PDCA1 depleting antibody (white circles) or isotype rat IgG (white triangles). *p < 0.05 and **p < 0.01 (log-rank Mantel–Cox test).
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substantiate the importance of this cytokine in the effective con-
trol of a chronic autoimmune disease such as T1D, as previously 
reported (33). Moreover, the inhibition of IDO1 proteasomal 
degradation may represent a valuable therapeutic option to be 
considered in associative regimens with low-dose anti-CD3, so 
perhaps to reduce the inflammatory side effects observed in some 
patients on optimal-dose anti-CD3 treatment (34).
DiscUssiOn
Initially, the antiproliferative capacity of proteasome inhibitors 
has received considerable attention because of the success of their 
first prototypical representative, BTZ, in the treatment of B cell 
and plasma cell-related hematological malignancies. However, 
the emerging role of immunoproteasome involvement in 
autoantigen presentation as well as the ability of BTZ to inhibit the 
activation of NF-κB and suppress the release of pro-inflammatory 
cytokines, including IL-6, have increased interest in exploring the 
therapeutic potential of proteasome inhibitors in inflammatory 
and autoimmune disease settings (35). Selective inhibitors of the 
immunoproteasome and constitutive proteasome have recently 
been tested in models of autoimmune disease and allograft 
survival (17, 36). In experimental settings of inflammation and 
autoimmunity, BTZ does ameliorate disease severity, yet it has not 
been possible to identify a unitary mechanism of action, leading 
to the conclusion that the drug affects chronic inflammation and 
autoimmunity in a pleiotropic and/or model-specific fashion (37).
In the NOD mouse model system of autoimmune diabetes, 
we have previously demonstrated that impaired tryptophan 
catabolism contributes to defective tolerance to pancreatic 
FigUre 5 | a combination of bortezomib (BTZ) and suboptimal anti-cD3 antibody restores normoglycemia in overtly diabetic mice. (a) Hyperglycemic 
female non-obese diabetic (NOD) mice (n = 8) were intraperitoneally administered with vehicle (white circles), BTZ at 0.1 mg/kg (white triangles) or 0.25 mg/kg (black 
squares). Blood glucose was monitored over time, and results are reported as diabetes incidence. (B) Hyperglycemic female NOD mice (n = 8) were administered 
with vehicle (white circles), with anti-CD3 alone (10 μg/mouse; black circles) or combined with BTZ at 0.1 mg/kg (white squares) or 0.25 mg/kg (black squares). 
Blood glucose was monitored over time and results are reported as diabetes incidence. *p < 0.05 (log-rank Mantel–Cox test). (c) Indoleamine 2,3-dioxygenase  
1 (IDO1) immunoblot analysis of cell lysates from pancreatic lymph nodes (pLNs) of mice treated as in panel (B). One representative experiment out of three is 
shown. (D) IDO1 activity measured in terms of kynurenine production in supernatant of cells from pLNs of mice treated as in panel (B) and cultured for 24 h. 
**p < 0.01 (one-way ANOVA and Dunnett’s multiple comparison test). (e) Detection of IL-6, IL-10, and TGF-β in supernatant of cells from pLNs of mice treated  
as in panel (B) and cultured for 24 h. *p < 0.05 and **p < 0.01 (one-way ANOVA and Dunnett’s multiple comparison test).
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antigens (9, 38). The condition results from a combination of 
functional anomalies, including poor signaling activity of IFN-γ 
and poor transcriptional activation of Ido1 (4), and increased 
proteasomal degradation of the IDO1 protein. The latter is largely 
sustained by high-level production of IL-6 (8, 39), which operates 
through SOCS3—a negative regulator of IDO1’s enzymatic and 
signaling functions (40)—which acts, in turn, to ubiquitinate 
and degrade IDO1. One major effect of the reduced tryptophan 
catabolic function by IDO1 could be the defective production of 
kynurenine-type ligands of the aryl hydrocarbon receptor (41), 
which is involved in the generation of regulatory T cells (42, 43).
Plasmacytoid DCs have an ambivalent role in the pathogenesis 
of autoimmune diabetes (44). The protective mechanisms are 
thought to involve inhibition of effector T cells, induction of regu-
latory T cells, and production of anti-inflammatory cytokines and 
IDO1. Although the exact mechanism of tolerance induction by 
pDCs in diabetes remains to be established, the intrinsic tolero-
genic properties of pDCs provide a promising, yet perhaps under-
estimated, target for therapeutic intervention. Here, we found that 
BTZ treatment in vitro rescued IDO1 protein expression in predia-
betic NOD pDCs, which were confirmed to manifest basally high 
transcriptional expression of Socs3, β-subunits of the immuno-
proteasome and the pro-inflammatory pathway of NF-κB. When 
administered in vivo to NOD mice, the BTZ-conditioned pDCs 
blocked the immunogenic presentation of a diabetogenic peptide, 
and BTZ itself would oppose diabetes onset in prediabetic mice. 
This was reflected in vitro by changes in the activation patterns of 
NF-κB family members and in cytokine secretion profiles—most 
notably, IL-6—and by generation of Foxp3+ regulatory T  cells. 
Nevertheless, the inhibition of IDO1 by 1-MT during the in vitro 
conditioning of pDCs with BTZ would not consistently abrogate 
BTZ effects, suggesting the involvement of additional mechanisms 
beside the IDO1-mediated effect of BTZ. Mice protected from 
diabetes by BTZ in vivo also displayed increased percentages of 
Foxp3+CD4+ and IDO1 protein expression in both pLNs and 
pancreata, and an increased systemic Kyn/Trp ratio. The in vivo 
effect of BTZ required IDO1-mediated tryptophan catabolism 
and immune regulatory pDCs. Although pDC-depleted NOD 
mice in the absence of BTZ treatment showed a reduction in 
diabetes incidence, as previously reported (31), depletion of pDCs 
in BTZ-treated NOD mice would abrogate the protective effect of 
the drug. Unlike inflammatory-prone pDCs, which contribute to 
the pathogenesis of autoimmune diabetes, the immune regulatory 
properties of BTZ-conditioned pDCs are pivotal in the preventive 
effect of the drug in autoimmune diabetes. BTZ, however, showed 
no therapeutic activity when administered alone to overtly dia-
betic mice. Nevertheless, its combination with suboptimal dosages 
of autoimmune-preventive anti-CD3 antibody resulted in disease 
reversal in 70% diabetic mice, a therapeutic effect similar to that 
afforded by full-dosage anti-CD3 (22).
Clinical trials in type 1 diabetes showed that adequate dosing of 
anti-CD3 resulted in improved C-peptide responses and reduced 
exogenous insulin need (34, 45). Teplizumab, in particular, has 
been shown to preserve β-cell function in patients, failing, how-
ever, to represent a “cure” for patients (46). Side effects, including 
fever, anemia, urticarial rash, and a high incidence of anti-drug 
antibody development, occur frequently in patients treated with 
Teplizumab. For safety reasons, the dose of anti-CD3 used in the 
phase 3 trials was reduced as compared with that used in the pilot 
studies and was therefore probably insufficient (47).
Thus, effective therapies in humans that ensure efficacy while 
minimizing side effects remain a challenge. In addition, mono-
therapy with anti-CD3 also has its limits from the perspective 
of targeting only a single arm of the immune process. For this 
reason, several recent experimental studies have been exploiting 
synergy between anti-CD3 and various immunotherapeutic 
modalities (48). Our current results show that a combination of 
BTZ and low-dosage anti-CD3 results in a marked increase in 
the therapeutic efficacy of the antibody. We speculate that the 
synergistic effect may stem from a two-pronged approach to the 
mechanisms whereby NOD pDCs affect CD4+ T-cell differen-
tiation toward a regulatory phenotype, by altering the cytokine 
milieu and the antigen presentation profile of the pDCs, via 
restoration of IDO1 functions, and by the non-lytic modulation 
of T cells by anti-CD3. Specifically, by reducing the proteolytic 
degradation of IDO1, BTZ might, at least in part, compensate for 
the defective Ido1 transcription by IFN-γ as well as for the IL-6/
SOCS3-driven degradation of the IDO1 protein.
In conclusion, our current data point to a potential for BTZ in 
the management of autoimmune diabetes in humans and, at the 
same time, they provide mechanistic into how the drug acts to 
restore immune homeostasis in autoimmune settings via poten-
tiation of the IDO1 tolerogenic mechanism.
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